Nebivolol-Induced Hepatoxicity: A Case Report.
| Autor: | Srour L; Department of Internal Medicine, University of Balamand, Beirut, Lebanon., Ali M; Department of Internal Medicine, University of Balamand, Beirut, Lebanon., Karam K; Department of Gastroenterology, University of Balamand, Beirut, Lebanon., Fiani E; Department of Gastroenterology, University of Balamand, Beirut, Lebanon. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European journal of case reports in internal medicine [Eur J Case Rep Intern Med] 2024 Oct 01; Vol. 11 (11), pp. 004866. Date of Electronic Publication: 2024 Oct 01 (Print Publication: 2024). |
| DOI: | 10.12890/2024_004866 |
| Abstrakt: | Nebivolol is a third-generation beta-blocker known for its high selectivity for beta-1 adrenergic receptors and its unique ability to induce vasodilation via nitric oxide (NO) release. Nebivolol, despite its favourable safety profile, can lead to significant liver injury. We describe the case of a 73-year-old hypertensive patient who developed significant liver enzyme elevations following the addition of nebivolol to her treatment regimen. Comprehensive workup ruled out other causes, leading to a diagnosis of drug-induced hepatotoxicity. Discontinuation of nebivolol resulted in normalization of liver enzymes. This case underscores the importance of monitoring liver function during beta-blocker therapy, particularly with nebivolol. Learning Points: Nebivolol, despite its favourable safety profile, can lead to significant liver injury.Clinicians should remain vigilant and consider routine liver function monitoring in patients prescribed nebivolol, particularly if they present with nonspecific symptoms or abnormal liver enzyme tests.Early recognition and prompt discontinuation of the offending agent are crucial in preventing severe outcomes. Competing Interests: Conflicts of Interests: The Authors declare that there are no competing interests. (© EFIM 2024.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|